When MIP3α-Gp100-Trp2 vaccine adjuvanted with CpG type C (henceforth referred to as “vaccine”) was combined with the drug treatments low-dose 5Aza-2’Deoxycytidine (5Aza) and a series of high and low doses of recombinant IFNα (IFN) (Fig. 1A), significantly greater anti-tumor activity was achieved, including increased dendritic cell (DC) and CD8+ T-cell infiltration into the tumor microenvironment (TME)[3, 8]. Here, IFNA1 is linked to neoplasm.